

Abstract Presentations

3. Alberto de la Hoz, Germany

Breathing and feeling well through universal access to right care



Efficacy of tiotropium/olodaterol compared with tiotropium in patients naïve to LAMA, LABA and ICS, and patients receiving only LAMA at baseline: pooled analyses of four clinical trials

R. Buhl, <u>A. de la Hoz¹</u>, F. Voß, D. Singh, G.T. Ferguson

27 June 2020

Disclosure: AdlH is an employee of Boehringer Ingelheim

¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany


Breathing and feeling well through universal access to right care

Introduction, Aim and Methods

- GOLD recommends LAMAs as the first-line maintenance treatment for most COPD patients; however, many patients remain symptomatic on monotherapy, so a step-up to dual bronchodilator therapy is recommended^{1–3}
- TONADO[®] and OTEMTO[®] were large Phase III clinical trials that evaluated the efficacy of LAMA/LABA combination (T/O) compared with LAMA monotherapy (tio) delivered via Respimat[®] in patients with moderate-to-very severe COPD^{4,5}

Aim: To compare the efficacy of T/O with tio in two COPD patient subsets:

- Patients not receiving maintenance treatment with LAMA, LABA or ICS (maintenance-naïve)
- Patients receiving only LAMA at baseline



COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; SGRQ, St. George's Respiratory Questionnaire; T/O, tiotropium/olodaterol; TDI, Transition Dyspnoea Index; tio, tiotropium. 1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. Available here: <u>https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf</u>; 2. Malerba M, et al. Front Pharmacol 2019; 10:390; 3. Miravitlles M, et al. Eur Respir J 2017; 49:1602200; 4. Buhl R, et al. Eur Respir J 2015; 45:969–979; 5. Singh D, et al. Resp Med 2015; 109:1312–1319.


Baseline characteristics

	Treatment-naïve at baseline		LAMA at baseline	
Characteristic	Tio 5 μg (n=560)	T/O 5/5 μg (n=518)	Tio 5 μg (n=151)	T/o 5/5 μg (n=148)
Male, n (%)	394 (70.4)	347 (67.0)	109 (72.2)	99 (66.9)
Age, years	62.8±8.6	62.9±8.5	65.2±8.0	65.9±8.7
Smoking status Ex-smoker, n (%) Current smoker, n (%)	304 (54.3) 256 (45.7)	264 (51.0) 254 (49.0)	97 (64.2) 54 (35.8)	77 (52.0) 71 (48.0)
Post-bronchodilator spirometry FEV ₁ , L FEV ₁ % predicted, % FVC, L FEV ₁ /FVC, %	1.489±0.534 52.754±15.118 3.051±0.827 49.102±12.212	1.464±0.526 52.603±14.939 3.010±0.872 49.042±11.602	1.491±0.523 54.291±14.584 3.176±0.855 47.179±11.518	1.440±0.483 54.456±13.798 3.069±0.846 47.309±10.656
GOLD stage, n (%) 1: FEV ₁ ≥80% 2: FEV ₁ 50–<80% 3: FEV ₁ 30–<50% 4: FEV ₁ <30%	2 (0.4) 329 (58.8) 187 (33.4) 42 (7.5)	0 (0.0) 301 (58.1) 177 (34.2) 40 (7.7)	0 (0.0) 94 (62.3) 44 (29.1) 13 (8.6)	0 (0.0) 96 (64.9) 44 (29.7) 8 (5.4)
SGRQ score	43.4±18.4	43.1±17.4	39.9±15.9	37.5±16.6
BDI score	6.5±2.2	6.5±2.2	7.0±2.1	7.2±1.9

Data are mean±SD unless stated otherwise.

BDI, Baseline Dyspnoea Index; FVC, forced vital capacity; SD, standard deviation.


Treatment differences in trough FEV₁



At Week 12, T/O compared with tio was associated with a significant increase from baseline in trough FEV₁

^aP<0.0001; ^bP=0.0004. CI, confidence interval; SE, standard error.

Treatment differences in SGRQ and TDI total score



At Week 12, T/O compared with tio was associated with <u>a significant improvement from baseline in SGRQ</u> and TDI total score

^aP=0.0096; ^bP=0.0280; ^cP=0.0158; ^dP=0.0001.

Responder analysis of SGRQ and TDI at Week 12

	% responder, T/O / tio	Odds ratio (95% Cl)	P value	Odds ratio (95% CI)
Maintenance-naïve at baseli	ne			
Trough FEV ₁	55.8 / 41.1	1.81 (1.42, 2.30)	<0.0001	
SGRQ total score	59.6 / 48.8	1.54 (1.20, 1.99)	0.0007	⊢●1
TDI score	63.3 / 55.0	1.43 (1.11, 1.85)	0.0057	⊢●1
LAMA at baseline				
Trough FEV ₁	68.5 / 40.9	3.14 (1.94, 5.06)	<0.0001	·
SGRQ total score	57.4 / 47.9	1.49 (0.93, 2.40)	0.0980	k
TDI score	57.1 / 31.5	2.81 (1.71, 4.60)	<0.0001	⊢

- T/O compared with tio resulted in a greater likelihood of being a trough FEV₁ responder, TDI responder and SGRQ responder in maintenance-naïve patients
- For patients with LAMA at baseline, a greater likelihood of being a trough FEV₁ responder, TDI responder and a trend towards a
 greater likelihood of being an SGRQ responder was observed with T/O compared with tio

 FEV_1 responder is defined as >100 mL change in trough FEV_1 from baseline; SGRQ responder is defined as ≥4-unit improvement of SGRQ total score from baseline; TDI responder is defined as ≥1-unit improvement in TDI score from baseline.

Conclusions

Initiation of maintenance treatment with T/O resulted in greater improvements in lung function, health status and breathlessness compared with tio in maintenance-naïve patients and patients receiving only LAMA at baseline

These results show that dual bronchodilation with T/O is a suitable choice for first-line maintenance treatment in maintenance-naïve patients with COPD

Patients treated with single bronchodilator therapy with LAMA would benefit from optimisation of treatment with dual bronchodilation with T/O